Sangamo Therapeutics (SGMOQ) FCF Margin (2010 - 2025)
Sangamo Therapeutics (SGMOQ) posted FCF Margin of 171.61% for Q4 2025, up 96.5% on a QoQ basis from 4902.75% in Q3 2025, and down 12194.0% year-over-year from N/an in Q4 2024.
Powered by 
Analysis
Sangamo Therapeutics (SGMOQ) FCF Margin (2010 - 2025) Analysis & Trends
Sangamo Therapeutics has reported FCF Margin for 16 years, with the latest figure at 171.61% in Q4 2025.
- On a quarterly basis, FCF Margin fell 12194.0% year-over-year to 171.61% in Q4 2025; TTM through Dec 2025 was 246.03%, a 12725.0% decrease from a year earlier, with the FY2025 full-year figure at 246.03%, down 12941.0% from the prior year.
- FCF Margin was 171.61% for Q4 2025 at Sangamo Therapeutics, up from 4902.75% in the prior quarter.
- The five-year high for FCF Margin was 23.89% in Q3 2024, with the low at 10212.68% in Q1 2024.
- Average FCF Margin over 5 years is 1466.46%, with a median of 222.79% recorded in 2021.
- The sharpest annual moves came in 2024 and 2025: FCF Margin sank 1016425 bps in 2024, then jumped 980282 bps in 2025.
- Over 5 years, FCF Margin stood at 198.57% in 2021, then retreated by 19 bps to 236.96% in 2022, then tumbled by 1000 bps to 2605.73% in 2023, then surged by 98 bps to 49.68% in 2024, then plunged by 245 bps to 171.61% in 2025.
- The last three FCF Margin figures came in at 171.61% (Q4 2025), 4902.75% (Q3 2025), and 98.46% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.26 Bn | 9.41 Bn | 112.79 Mn | 59.74% |
| 2 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -826.50% |
| 3 | Iovance Biotherapeutics | 3.80 Bn | 3.50 Bn | 55.72 Mn | -66.71% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -3.46% |
| 5 | uniQure | 3.04 Bn | 3.04 Bn | 5.49 Mn | -497.31% |
| 6 | Beam Therapeutics | 2.64 Bn | 2.64 Bn | - | -13,981.63% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | -33.11% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 48.98% |
| 9 | Vericel | 1.98 Bn | 1.82 Bn | 56.40 Mn | 18.67% |
| 10 | Sangamo Therapeutics | 43.99 Mn | 23.04 Mn | - | -171.61% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -171.61% |
| Sep 30, 2025 | -4,902.75% |
| Jun 30, 2025 | -98.46% |
| Mar 31, 2025 | -409.86% |
| Dec 31, 2024 | -49.68% |
| Sep 30, 2024 | 23.89% |
| Jun 30, 2024 | -7,544.10% |
| Mar 31, 2024 | -10,212.68% |
| Dec 31, 2023 | -2,605.73% |
| Sep 30, 2023 | -532.42% |
| Jun 30, 2023 | -969.29% |
| Mar 31, 2023 | -48.43% |
| Dec 31, 2022 | -236.96% |
| Sep 30, 2022 | -219.32% |
| Jun 30, 2022 | -202.29% |
| Mar 31, 2022 | -218.96% |
| Dec 31, 2021 | -198.57% |
| Sep 30, 2021 | -226.26% |
| Jun 30, 2021 | -214.66% |
| Mar 31, 2021 | -291.10% |